跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2021-001790-23-ES
EUCTR2021-001790-23-ES进行中（未招募）1 期

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1047 in subjects with malignant solid tumors - GEN1047 for Solid Tumors – FIH trial

Genmab A/S0 个研究点目标入组 380 人开始时间: 2021年7月14日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
进行中（未招募）
发起方
Genmab A/S
入组人数
380
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •Criteria Applicable only to Dose Escalation Part
  • •Subject must have histologically or cytologically confirmed solid tumor(s) in any of the following selected indications for which there is no further available standard therapy likely to confer clinical benefit (or subject is not a candidate or refuses such available therapy), and for whom, in the opinion of the investigator, experimental therapy with GEN1047 may be beneficial (breast cancer, uterine cancer, ovarian cancer, non-small-cell lung cancer [NSCLC], cervical cancer, head and neck squamous cell carcinoma [HNSCC], urothelial cancer; cholangiocarcinoma [CCA]).
  • •Criteria Applicable only to Expansion Part
  • •Subject must have an advanced or metastatic, pathologically confirmed diagnosis of one of the following tumors for which there is no further available standard therapy likely to confer clinical benefit (or subject is not a candidate or refuses such available therapy), and for whom, in the opinion of the investigator, experimental therapy with GEN1047 may be beneficial (breast cancer, uterine cancer, ovarian cancer, NSCLC, cervical cancer, HNSCC, urothelial cancer; CCA). For all indications: Subjects may have received up to 4 prior systemic treatment regimens for advanced/metastatic disease (maintenance treatment is considered being part of 1 treatment line).
  • •Criteria Applicable to Dose Escalation and Expansion Parts
  • •Subjects with ovarian cancer:
  • •- Must have documented progressive disease (PD) on or after last prior treatment and within 60 days of Screening.
  • •- CA-125 positivity according to the Gynecologic Cancer Intergroup Guideline (GCIG) with a pretreatment sample that is at least twice the upper limit of the reference range and within 2 weeks before starting the treatment. Note: Subjects are not evaluable by CA-125 if they have received mouse antibodies (unless the assay used has been shown not to be influenced by human anti-mouse antibody) or if there has been medical and/or surgical interference with their peritoneum or pleura during the previous 28 days (eg, paracentesis).
  • •- Isolated GCIG CA-125 progression does NOT qualify for trial entry.
  • •Must be at least 18 years of age.
  • •Must have either recurrence after, or progression on or lack of response to established standard of care (SOC) anticancer therapies; or are deemed intolerant to or ineligible for, standard curative therapy in the recurrent setting.
  • •Must have at least 1 measurable lesion per RECIST v1.1. The measurable lesion(s) must be outside the field of radiation therapy (RT) if there was prior treatment with RT.
  • •Must have an Eastern Cooperative Oncology Group performance status (ECOG- PS) score of 0 to 1 at Screening and on Cycle 1 Day 1 (C1D1) pretreatment. Note: Do not perform C1D1 ECOG-PS if within 5 days of Screening ECOG-PS.
  • •Must provide a tumor tissue sample during the Screening period and prior to C1D1. A fresh biopsy obtained during Screening may be provided; if a fresh biopsy cannot be obtained, the most recent archival tissue can be submitted if acquired =6 months prior to C1D1. Note: Tumor tissue sample acquired >6 months prior to C1D1 requires sponsor approval on a case-by-case basis.
  • •Must have acceptable laboratory parameters according to the list below:
  • •- Glomerular Filtration Rate: =30 mL/min (estimated using Cockcroft-Gault formula)
  • •- Total Bilirubin: =1.5× institutional ULN (except Gilbert syndrome, then direct bilirubin =2× institutional ULN)
  • •- Aspartate Aminotransferase (AST): =2.

排除标准

  • •Cardiovascular Disease
  • •- Symptomatic congestive heart failure (NYHA grade III or IV), unstable angina pectoris or cardiac arrhythmia.
  • •- Myocardial infarction within 6 months of start of GEN1047.
  • •- Uncontrolled hypertension (systolic =160 mmHg and/or diastolic =100 mmHg), despite optimal management. QTc interval >480 msec using Fridericia's QT correction formula.
  • •- Other cardiac disease not listed that, in the opinion of the investigator, is/are clinically significant and/or unacceptable.
  • •Central Nervous System
  • •- History of intracerebral arteriovenous malformation, cerebral aneurysm, new (within 6 months) or symptomatic brain metastases, spinal cord compression (from disease), or stroke. Transient ischemic attack >1 month before Screening is allowed.
  • •- Subjects with unstable CNS metastases and active or history of carcinomatous meningitis are excluded. Subjects with prior treated brain metastases are permitted if they are radiologically stable (no evidence of progression) for at least 28 days by repeat imaging before C1D1. Subjects should be clinically stable and not undergoing steroid taper or have received stereotactic radiation or whole-brain radiation within 14 days before C1D1. Chronic steroid therapy is acceptable provided the dose is stable in the 14 days prior to C1D1 (=10 mg prednisone daily or equivalent, corresponding to a maximum exposure of =140 mg within 14 days).
  • •- Subject with new or progressive brain metastases. Spinal cord metastasis is acceptable. Subjects with spinal cord compression are excluded.
  • •Subject has received any of the following in the stated timeframes:
  • •- Radiotherapy within 14 days of first GEN1047 dose. Palliative radiotherapy is allowed.
  • •- RANK-L inhibitors and bisphosphonates (if on stable dose for =4 weeks) are permitted in this trial. Initiation of growth factors and bisphosphonates is not allowed during the first 4 weeks of GEN1047 administration, unless agreed by the investigator and sponsor medical monitor.
  • •- Treatment with investigational or non-investigational anticancer agents (including investigational vaccines) or used an invasive investigational medical device within 28 days or 5 half-lives, whichever is shorter, before the first GEN1047 dose or is currently enrolled in an interventional trial. Subjects in the follow-up phase of an interventional trial may participate if they have not received an investigational agent within 28 days of the first GEN1047 dose.
  • •- Prophylaxis with live, attenuated vaccines within 28 days of the first dose of GEN1047; or prophylaxis with the first and/or subsequent injection(s) of SARS-CoV-2 nucleic acid vaccine within 28 days prior to first dose of GEN1047.
  • •- Chronic systemic immunosuppressive corticosteroids, ie, prednisone >10 mg daily (or equivalent) or a cumulative dose >140 mg prednisone within 14 days (or equivalent) before the first GEN1047 dose. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is permitted.
  • •- Has received granulocyte colony-stimulating factor (G-CSF) or granulocyte/macrophage colony stimulating factor support within 2 weeks prior to the first dose of GEN1047 or being chronically transfusion dependent.
  • •- Any prior therapy with an antibody targeting CD3 or other T cell activating surface marker.
  • •Toxicities from previous anticancer therapies that have not resolved to baseline levels or to = grade

研究者

发起方
Genmab A/S

相似试验

进行中（未招募）
1 期
First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1029 in patients with malignant solid tumorsMalignant solid tumors: Patients with advanced and/or metastatic colorectal cancer (CRC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), renal cell carcinoma (RCC), gastric (incl. esophagogastric junction) cancer, pancreatic cancer or urothelial cancer.MedDRA version: 20.1 Level: LLT Classification code 10065143 Term: Malignant solid tumour System Organ Class: 100000004864
EUCTR2017-001394-16-ESGenmab B.V.206
进行中（未招募）
1 期
A Safety study of GEN1044 in patients with malignant solid tumors.
EUCTR2019-003998-26-ESGenmab A/S378
招募中
1 期
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
CTIS2023-509059-15-00Genmab A/S427
招募中
1 期
GEN1047 for Solid Tumors - First in Human (FIH) TrialMalignant Solid TumorsMedDRA version: 21.1Level: LLTClassification code: 10065147Term: Malignant solid tumor Class: 10029104
CTIS2024-510722-10-00Genmab A/S333
进行中（未招募）
1 期
First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1029 in patients with malignant solid tumorsMalignant solid tumors:Patients with advanced and/or metastatic colorectal cancer (CRC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), renal cell carcinoma (RCC), gastric (incl. esophagogastric junction) cancer, pancreatic cancer or urothelial cancer.MedDRA version: 21.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 100000004864
EUCTR2017-001394-16-GBGenmab B.V.48